

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<p>Bombay Stock Exchange Limited 1<sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p><b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p><b>Kind Attn.:</b> Famroze Pochara Asst. Vice President</p>
<p><b>Date:</b> February 19, 2016</p>	
<p><b>Re.:</b> Press Release.</p>	


Dear Sir / Madam,

We enclose herewith a copy of press release dated February 19, 2016 under the title **“Zydus Cadila has received approval from the USFDA to market Doxycycline Capsules USP from its formulation manufacturing facility at SEZ”**. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For **Cadila Healthcare Limited**



**Upen H. Shah**  
Company Secretary

Encl.: As above.

Zydus to commence supplies to the US market from its formulation  
manufacturing facility at SEZ

*Receives approval for Doxycycline Capsules USP*

Ahmedabad, 19 February 2016

Zydus Cadila has received approval from the USFDA to market Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg. The drug falls in the anti-bacterials segment.

With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad.

The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*